ArticleEye (London, England)2026
Ocular surface inflammatory cytokines as a biomarker for retinopathy of prematurity.
Article in Eye (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Retinopathy of prematurity: Moving beyond oxygen.Early human development · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundROP is a leading cause of childhood blindness, with inflammation influencing its progression. Tear fluid serves as a non-invasive medium for assessing biomarkers.
aimThis study examines key inflammatory cytokines in tear fluid to identify biomarkers for ROP progression and severity.
methodsEighty preterm infants were grouped by ROP severity (No, Mild, Moderate, Severe; n = 20 each). Tear fluid cytokine levels were measured via ELISA and compared using one-way ANOVA with Bonferroni-adjusted post hoc tests.
resultsThe levels of IL-1, IL-6, and TNF-α were significantly different across ROP severity groups; higher concentrations in more severe stages of ROP/moderate and severe than those in no ROP and mild ROP. However, no significant differences were found among the groups regarding IL-10, IL-17, and IL-22. In pairwise comparisons, the levels of IL-1 and IL-6 in most of the ROP severity groups showed significant differences according to the Bonferroni post hoc analysis, while no significant differences were observed regarding IL-10, IL-17, and IL-22.
conclusionThe study further reveals that increased levels of the pro-inflammatory cytokines IL-1, IL-6, and TNF-α in tear fluid correlate with the severity of ROP. These findings suggest that tear fluid inflammatory cytokines may be regarded as potential biomarkers in the diagnosis and follow-up of ROP. This non-invasive approach presents a new opportunity for monitoring the disease process and assisting in clinical decisions. These observations need further confirmation and studies on their clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.